BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18193422)

  • 1. Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
    Kondadasula SV; Varker KA; Lesinski GB; Benson DM; Lehman A; Olencki T; Monk JP; Kendra K; Carson WE
    Cancer Immunol Immunother; 2008 Aug; 57(8):1137-49. PubMed ID: 18193422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
    Carson WE; Fehniger TA; Caligiuri MA
    Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
    Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
    Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
    Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
    J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
    Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA
    J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood.
    Hodge S; Hodge G; Flower R; Han P
    Scand J Immunol; 2000 Jan; 51(1):67-72. PubMed ID: 10632978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
    Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
    Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipopolysaccharide stimulates the proliferation of human CD56+CD3- NK cells: a regulatory role of monocytes and IL-10.
    Goodier MR; Londei M
    J Immunol; 2000 Jul; 165(1):139-47. PubMed ID: 10861046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes.
    Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J
    Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Truncated thioredoxin (Trx80) induces differentiation of human CD14+ monocytes into a novel cell type (TAMs) via activation of the MAP kinases p38, ERK, and JNK.
    Pekkari K; Goodarzi MT; Scheynius A; Holmgren A; Avila-Cariño J
    Blood; 2005 Feb; 105(4):1598-605. PubMed ID: 15494431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
    Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
    Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The functional characterization of interleukin-10 receptor expression on human natural killer cells.
    Carson WE; Lindemann MJ; Baiocchi R; Linett M; Tan JC; Chou CC; Narula S; Caligiuri MA
    Blood; 1995 Jun; 85(12):3577-85. PubMed ID: 7540068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: role of cell adhesion to endothelium.
    Salvo G; Samoggia P; Masciulli R; Boccoli G; Allavena P; Mariani G; Bullo A; Montesoro E; Bulgarini D; Carlini P
    Eur J Cancer; 1992; 28A(4-5):818-25. PubMed ID: 1524901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of monocytes in the expansion of human activated natural killer cells.
    Miller JS; Oelkers S; Verfaillie C; McGlave P
    Blood; 1992 Nov; 80(9):2221-9. PubMed ID: 1421393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
    J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12.
    Parihar R; Trotta R; Roda JM; Ferketich AK; Tridandapani S; Caligiuri MA; Carson WE
    Cancer Res; 2005 Oct; 65(19):9099-107. PubMed ID: 16204085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway.
    Yu TK; Caudell EG; Smid C; Grimm EA
    J Immunol; 2000 Jun; 164(12):6244-51. PubMed ID: 10843677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.